These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 21050114)

  • 1. Use of high-dose 4-hour infusion of doripenem, in combination with fosfomycin, for treatment of carbapenem-resistant Pseudomonas aeruginosa pneumonia.
    Apisarnthanarak A; Mundy LM
    Clin Infect Dis; 2010 Dec; 51(11):1352-4. PubMed ID: 21050114
    [No Abstract]   [Full Text] [Related]  

  • 2. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin.
    Apisarnthanarak A; Mundy LM
    Int J Antimicrob Agents; 2012 Mar; 39(3):271-2. PubMed ID: 22236455
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of doripenem in an experimental model of resistant Pseudomonas aeruginosa pneumonia.
    Bretonnière C; Jacqueline C; Caillon J; Guitton C; Desessard C; Le Mabecque V; Miégeville AF; Villers D; Potel G; Boutoille D
    J Antimicrob Chemother; 2012 Mar; 67(3):780-1. PubMed ID: 22184470
    [No Abstract]   [Full Text] [Related]  

  • 4. Efficacy of doripenem in the treatment of Pseudomonas aeruginosa experimental pneumonia versus imipenem and meropenem.
    Bretonnière C; Jacqueline C; Caillon J; Guitton C; Le Mabecque V; Miégeville AF; Villers D; Potel G; Boutoille D
    J Antimicrob Chemother; 2010 Nov; 65(11):2423-7. PubMed ID: 20858688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effects of fosfomycin and carbapenems against carbapenem-resistant Pseudomonas aeruginosa clinical isolates.
    Kunakonvichaya B; Thirapanmethee K; Khuntayaporn P; Montakantikul P; Chomnawang MT
    Int J Antimicrob Agents; 2015 May; 45(5):556-7. PubMed ID: 25724628
    [No Abstract]   [Full Text] [Related]  

  • 6. Optimizing intravenous fosfomycin dosing in combination with carbapenems for treatment of Pseudomonas aeruginosa infections in critically ill patients based on pharmacokinetic/pharmacodynamic (PK/PD) simulation.
    Asuphon O; Montakantikul P; Houngsaitong J; Kiratisin P; Sonthisombat P
    Int J Infect Dis; 2016 Sep; 50():23-9. PubMed ID: 27418581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emergence of carbapenem resistance in Pseudomonas aeruginosa isolates from a patient with cystic fibrosis in the absence of carbapenem therapy.
    Wolter DJ; Acquazzino D; Goering RV; Sammut P; Khalaf N; Hanson ND
    Clin Infect Dis; 2008 Jun; 46(12):e137-41. PubMed ID: 18462098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation.
    Michalopoulos A; Virtzili S; Rafailidis P; Chalevelakis G; Damala M; Falagas ME
    Clin Microbiol Infect; 2010 Feb; 16(2):184-6. PubMed ID: 19694767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Importance of appropriate carbapenem use to reduce carbapenem--resistant Pseudomonas aeruginosa].
    Furukawa K
    Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():258-64. PubMed ID: 17455627
    [No Abstract]   [Full Text] [Related]  

  • 10. Metallo-beta-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in Brazil.
    Viana Vieira V; Lourenço da Fonseca E; Paulo Vincente AC
    Clin Microbiol Infect; 2005 Nov; 11(11):937. PubMed ID: 16216114
    [No Abstract]   [Full Text] [Related]  

  • 11. Change in antipseudomonal carbapenem susceptibility in 25 hospitals across 9 years is not associated with the use of ertapenem.
    Eagye KJ; Nicolau DP
    J Antimicrob Chemother; 2011 Jun; 66(6):1392-5. PubMed ID: 21459897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
    Peña C; Guzmán A; Suarez C; Dominguez MA; Tubau F; Pujol M; Gudiol F; Ariza J
    Antimicrob Agents Chemother; 2007 Jun; 51(6):1967-71. PubMed ID: 17420207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on the treatment of Pseudomonas aeruginosa pneumonia.
    El Solh AA; Alhajhusain A
    J Antimicrob Chemother; 2009 Aug; 64(2):229-38. PubMed ID: 19520717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa.
    Shigemi A; Matsumoto K; Yaji K; Shimodozono Y; Takeda Y; Miyanohara H; Kawamura H; Orita M; Tokuda K; Nishi J; Yamada K
    Int J Antimicrob Agents; 2009 Dec; 34(6):589-91. PubMed ID: 19748231
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic heterogeneity of carbapenem-resistant Pseudomonas aeruginosa isolates co-infecting the cerebrospinal fluid of a pediatric patient.
    Gaspar EB; Neves PR; Levy CE; Mamizuka EM; Lincopan N
    Diagn Microbiol Infect Dis; 2011 Aug; 70(4):568-70. PubMed ID: 21429695
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular epidemiology and mechanisms of carbapenem resistance in Pseudomonas aeruginosa isolates from Chinese hospitals.
    Wang J; Zhou JY; Qu TT; Shen P; Wei ZQ; Yu YS; Li LJ
    Int J Antimicrob Agents; 2010 May; 35(5):486-91. PubMed ID: 20185276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A highly carbapenem-resistant Pseudomonas aeruginosa isolate with a novel blaVIM-4/blaP1b integron overexpresses two efflux pumps and lacks OprD.
    Maniati M; Ikonomidis A; Mantzana P; Daponte A; Maniatis AN; Pournaras S
    J Antimicrob Chemother; 2007 Jul; 60(1):132-5. PubMed ID: 17483142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
    Chastre J; Wunderink R; Prokocimer P; Lee M; Kaniga K; Friedland I
    Crit Care Med; 2008 Apr; 36(4):1089-96. PubMed ID: 18379232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid selection of carbapenem-resistant Pseudomonas aeruginosa by clinical concentrations of ertapenem.
    Vainio S; van Doorn-Schepens M; Wilhelm A; Vandenbroucke-Grauls C; Murk JL; Debets-Ossenkopp Y
    Int J Antimicrob Agents; 2013 May; 41(5):492-4. PubMed ID: 23453616
    [No Abstract]   [Full Text] [Related]  

  • 20. Risk factors for carbapenem-resistant Pseudomonas aeruginosa infection in a tertiary care hospital in Serbia.
    Djordjevic Z; Folic M; Ruzic Zecevic D; Ilic G; Jankovic S
    J Infect Dev Ctries; 2013 Sep; 7(9):686-90. PubMed ID: 24042106
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.